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  - 1 - EXECUTIVE SUMMARY 
 
  The diffusion of estrogen from a contraceptive ring into the body was modeled to 
check company claims that the ring provides a low-dose flow of drug at constant levels 
for 21 days after a short initial period.  An axi-symmetric geometry was used, illustrating 
the diffusion of estrogen out of the cross-section of the ring and through a mucosal layer, 
as well as the diffusion and absorption of the drug in the tissue region, which is the case 
for ¾ of the ring’s surface area.  A non-dimensionalized governing equation, with a 
transient, diffusion, and negative source term, was used to the model the system.  The 
source term was chosen by iterating, while the other terms were found or interpolated 
from scientific papers.  After sensitivity analysis, the concentration of the drug in the 
tissue was found to remain constant after 4 days.  In fact, it remained constant for 28 
days, another claim of the company.  The concentration of estrogen, a known carcinogen 
that can cause mood swings, nausea, and headaches at elevated or fluctuating levels, is at 
a lower level than other available hormonal contraceptives, supporting that it is a safer 
method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  - 2 - INTRODUCTION 
 
Many women use contraceptive methods that involve the hormones estrogen and 
progestin, which prevent the ovaries from developing and releasing mature eggs.  This, 
therefore, prevents conception.  Currently there are two well established types of birth 
control on the market.  These possibilities are the pill form where the user ingests a large 
dose once a day for 21 days or the birth control patch is placed on the skin every week for 
three weeks out of the month. Women can also receive hormone shots or implants that 
last for four months.  However, these methods only allow a menstrual cycle every four 
months, so they are difficult to compare to the other methods.  All of these other methods 
can cause side effects such as headaches, blood clots, nausea, and breakthrough bleeding. 
However, there is a new form of birth control that comes in a flexible thin ring that is 
inserted into the vagina below the cervix. This ring is designed to releases a continuous 
low dose of hormone that is absorbed by the vagina and distributed into the blood stream.  
The ring actually releases two derivatives of estrogen and progestin known as 
etonogestrel and ethinyl estradiol (Organon USA Inc. 2005).   See Figure 1 for the 
chemical structures of both of these compounds.  Because the ring is only changed once a 
month, it ceases the fluctuation of hormone levels that is normal in the other birth control 
methods.  
 
 
Figure 1:  Chemical structures of Etonogestrel and Ethinyl Estradiol. 
 
OBJECTIVES 
 
¾  To compare the NuvaRing to other forms of contraception like the daily pill 
and the weekly patch. 
¾  To model the release of the hormones, estrogen and progestin, showing that 
there is a constant rate of release. 
¾  To determine whether or not the NuvaRing, as it is claimed to, can still release 
high enough hormone levels to still act as a contraceptive during the last 7 
days of the 28-day menstrual cycle. 
 
 
 
  - 3 - PROBLEM DEFINITION / SCHEMATIC 
 
When this contraceptive device is placed inside the body, the two different 
hormones diffuse out of the circular ring.  The physical dimensions of the flexible ring 
are an outer diameter of two inches and a cross-sectional diameter of 1/8 inch (Organon 
USA Inc. 2005, See).  A more precise geometric schematic can be seen in Figure 2 
(Organon USA Inc. 2005).  The ring is designed to set the diffusion rate at a constant 
average of 0.120 mg of Etonogestrel and 0.015 mg of Ethinyl Estradiol per day over the 
21-day period (Organon USA Inc. 2005).  These two drugs are embedded in a polymeric 
matrix of Ethylene Vinyl Acetate (EVA) copolymers and magnesium stearate (Organon 
USA Inc. 2005).  Etonogestrel has a diffusion constant of 1.54 x10
-9cm
2/s in EVA (van 
Laarhovan 2002).  The diffusion constant of Ethinyl Estradiol in EVA is not specifically 
stated in the literature.  However, through some simple calculations and comparison to 
similar types of drugs in comparable tissues, it was found that Ethinyl Estradiol’s 
diffusion constant in the EVA is about the same as Etonogestrel.  In the vaginal tissue the 
two drugs have an estimated diffusion coefficient of 1.5 x10
-7cm
2/s.  Again, this value 
was interpolated from the diffusion constants of the same drugs in similar tissues.  Since 
both drugs have the same diffusion coefficients and they only differ in their initial 
concentrations in the ring, the simulation model only monitored the Etonogestrel 
concentrations.       
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
Figure 2: Dimensions of the birth control ring. 
 
 
The drug diffusion out of the polymer ring and into the surrounding tissues occurs 
so that after 2-3 days the concentration of the drug reaches a maximum level.   
The concentration then levels off to a fairly constant blood concentration for the 
remainder of the 21 day time period (Organon USA Inc. 2005).  Therefore, a transient 
time concentration model was used for this problem.  However, the NuvaRing Company 
claims that the ring will safely function up to 7 days past the prescribed 21 day period.  In 
  - 4 - order to check the validity of this claim, the model was monitored to the 28 day mark.  A 
distribution of blood concentration levels can be seen in figure 3, borrowed from the 
physician’s prescription manual for the NuvaRing (Organon USA Inc. 2005).   
 
 
Figure 3: Concentration levels of Etonogestrel and Ethinyl Estradiol throughout the 21-
day cycle.   
 
Metabolic information is available for the drugs in the blood, but there is nothing 
to suggest that the hormones are degraded before reaching the bloodstream.  Therefore, it 
can assumed that there is no generation or degradation reaction in the polymer or tissue.  
However, the drugs are absorbed by the capillaries in the tissue.  To account for this in 
the design, a negative source term was used in the tissue region.  This source term will 
represents the capillaries that run throughout the tissue which are removing the drug 
continuously over time.  Another assumption is that there is no convection due to the 
protected environment of the ring.  Furthermore, diffusion values and length scales are 
very small for this problem, so a non-dimensionalized form of the governing equation 
was used.  The final governing equation is: 
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  Using FIDAP, this hormone delivery system was modeled to determine whether 
or not a constant rate of hormone release is achievable.   It was assumed that hormone 
delivery is carried out entirely by diffusion, which was examined this through differences 
in concentrations between the ring and the surrounding environment.  Looking at figures 
4 and 5, it is seen that approximately ¾ of the rings surface is in contact with the mucosal 
fluid region (0.5mm thick) and then the muscular vaginal tissue (3.2 mm thick) 
(Tulikangas 2001).  The remaining ¼ of the surface is exposed solely to vaginal fluid, 
which is assumed to be the same mucosal fluid.  Therefore, diffusion will occur through 
these mediums accordingly.  The initial concentration of the drugs were assumed to be 
zero in the tissues and at a universally distributed constant in the ring polymers. It has 
been found that the initial amounts of Etonogestrel and Ethinyl Estradiol is 11.7 mg and 
2.7 mg respectively (Bellamy 2006).  Using these values with the size of the ring, it was 
  - 5 - determined that the initial concentrations in the ring were 9256.329 g/m
3 for Etonogestrel 
and 2136.076 g/m
3 for Ethinyl Estradiol.  Published literature suggests that is this is a 
safe assumption.           
 
  Conc. = 0
Flux = 0
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Diagram of the vaginal cavity.     Figure 5: 2-D cross section of the 3-D ring          
showing the Tissue thicknesses and 
dimensions and boundary conditions. 
 
To model this geometry, an axi-symmetric view of the problem was used.  Figure 
6 represents the 3D geometry of the ring and the surrounding tissue.  A cross section of 
this was used to create the 2-D axi-symmetric geometry which is found in Figure 5.  The 
geometry is divided into 3 separate regions: ring, mucus, and tissue. 
 
 
 
Figure 6: 3-D shape of ring frame. 
 
 
 
 
 
 
 
 
  - 6 - MESH 
 
Figure 7 represents the geometry and mesh created in GAMBIT using the 2D-
axisimmetric geometry assumed. The computational region is set above the axis of 
rotation to create the torus shape.  The three regions of the geometry are labeled in Figure 
7 to demonstrate the 2-D geometry relationships present. 
 
         
TISSUE 
RING 
MUCUS 
 
Figure 7: Mesh of ring and   Figure 8: Mesh of ring and surrounding 
surrounding tissue in GAMBIT.                     tissue in FIDAP. 
 
Figure 8 is the meshed geometry created in FIDAP.  The three regions of the geometry 
are accented in different colors.  The blue region is the tissue, the green the mucosal 
region, and the red is the ring. 
 
 
  - 7 - RESULTS AND DISCUSSION 
 
  The main purpose of this study is to demonstrate the constant hormone level that 
the birth control ring releases. All properties, boundary conditions, initial conditions, and 
governing equations used to simulate the problem are stated in Appendix A.  Since it was 
found that both Etonogestrel and Ethinyl Estradiol have the same diffusivity in the 
system, only the diffusion of Etonogestrel was analyzed because Ethinyl Estradiol would 
be exactly the same.  
 
  The first step in the analysis of the model was to determine the magnitude of the 
source term that would be necessary to accurately model the physical process of 
continuous drug removal from the tissue region.  To correctly identify this, a known 
value was necessary for comparison.  Using the published data on the release rate of 
Etonogestrel from the ring and a simple calculation of the surface are of a toriod with the 
dimensions of the ring, the average flux over time out of the ring was calculated to be 
about 9596.48 (Non-dimensional). To do this comparison, the simulation was run over 
the 21-day period for different value of the source term and the flux was calculated after 
each simulation.  Through iterations of this process, it was determined that a non-
dimensional source term of about -300 would give an average flux out of the ring within 
an order of magnitude of the published value.  
 
The current simulation was run for a 21-day period. Readings were taken at Day 
1, 3, 4, 10, and 21 for Etonogestrel. The concentration through the tissue follows a 
sigmoidal curve that plateaus off after approximately 4 days, which follows information 
from published literature. The concentration level in the ring remains high and the 
diffusion is very small out of the ring so that it lasts for the entire 21 days.   
 
  The graphs below represent the diffusion of the drug out of the ring through the 
tissues.  By the time Etonogestrel reaches the outer edge of the tissue it has been removed 
from the system and is assumed to have entered the bloodstream by absorption.  Figure 9 
below shows the change in concentration of Etonogestrel at the 5 different time 
measurements. Note that throughout the simulation, the right side of the ring region has a 
slightly lower concentration of the drug (can be seen by the faintly non-circular shape of 
the ring region) because the mucus has a high diffusion constant in the mucus region, 
therefore more of the drug has diffused out. 
 
The measurement taken at Day 1, shows that the ring still contains most of the 
drug and that only a slight amount has diffused out of the polymer matrix.  Most of the 
diffusion that has occurred has only entered the thin mucosal region surrounding the ring 
itself at this point in time.  Readings taken at Day 3 and 4 are very similar to Day 1 
except more of the drug has left the ring’s matrix and has diffused through the tissue.  
This can be seen by the slightly decreased size of the ring’s region and if you examine the 
graphs closely, you can tell that the mucus region on the right side of the graphs does 
have a slightly higher concentration.  To fully see how the mucus region does actually 
contain a higher concentration please reference Appendix C.  Day 10 displays a much 
more dramatic change in concentration then has been seen so far.  A lot of the drug has 
  - 8 - now left the ring and has been removed from the system.  Finally by Day 21, it can be 
seen that the concentration in the ring polymer matrix has been significantly reduced in 
comparison to the concentration in the surrounding tissue.  Additionally, note that in all 
of these plots, the concentration in the tissue region is almost uniform, which is what was 
expected and desired for this drug release system. 
  
a)   b)  
 
c)   d)  
 
e)   
Figure 9: Concentration differences for species 1, Etonogestrel, at times: 
a) t = 86400s (1 day) = 0.005276,      b) t = 259200s (3 days) = 0.15829, 
c) t = 345600s (4 days) = 0.02111,   d) t = 864000s (10 days) = 0.05276, 
e) t = 864000s (21 days) = 0.11087 
  - 9 -   To examine the differences in concentration of the two drugs over the 21 day 
period, a history plot was analyzed.  See Figure 10 below for details.  The readings were 
taken at the middle of the tissue region and at the center of the ring.  The middle of the 
tissue can be assumed to be a fair estimate of the concentration in blood stream over time.  
Even if the concentration in the blood does not match with this value, the change over 
time in concentration in the tissue will give an estimate of how constant the level of 
hormone is in the blood stream.  It was found that after about 4 days the concentration at 
the outer edge of the tissue levels off and slowly approaches a constant value.  This 
agrees with data found in the literature that states that the level of hormone found in the 
blood stream reaches a constant level about 4 days after ring use is initiated.   
 
 
 
Figure 10: Change in Etonogestrel at middle of tissue layer over the 21 day period. 
 
 
 
 
 
 
 
 
 
 
  - 10 -   Additionally, a history plot was created that simultaneously graphed the 
concentration of Etonogestrel in several different places throughout the model to compare 
the overall levels of the drug.  This can be seen below in Figure 11.  From this analysis it 
can easily be seen that the overall concentration in the tissue and mucus stay fairly 
constant over the 21 day period.   However the ring’s concentration of Etonogestrel drops 
off after several days of use as would be expected.  Finally, note that the concentration at 
the outer edge of the tissue region stays at zero for the entire 21 day period.  This displays 
that the previously stated boundary condition has been successfully fulfilled in the model. 
 
 
 
Figure 11: Change in Etonogestrel at outer edge of tissue layer (Light Green), inner edge 
of tissue (Blue), center of the ring (Green), and in the mucosal region (Orange) over the 
21 day period. 
 
Literature suggests that the ring will also last for an additional 7 days after the 21 
day suggest use period, in case the ring is misused or somehow forgotten.  This claim was 
also examined by allowing the simulation to run to 28 days. The results of this can be 
seen below in Figure 12 and Figure 13. 
  - 11 -  
 
Figure 12: Change in Etonogestrel at outer edge of tissue layer (Light Green), inner edge 
of tissue (Blue), center of the ring (Green), and in the mucosal region (Orange) between 
day 21 and day 28 of the simulation period. 
 
 
 
Figure 13: Etonogestrel concentration variation at Day 28. 
 
  From this analysis it was determined that the ring does in fact continue to work 
for the additional 7 days.  From the figures above it can easily be seen that the 
concentration in the tissue region maintains the constant level of hormone for the 
additional 7 days.  The concentration in the ring does continue to drop off linearly during 
the period.  Further time analysis was not completed because there is no claim or proof 
that the ring will work correctly for any longer than the max of 28 days.   
  - 12 - SENSITIVITY ANALYSIS 
 
The first step in the sensitivity analysis for this study was to determine the number 
of elements needed for the mesh to converge.  Six different meshes were created to 
analyze this sensitivity. The number of elements in each mesh was counted and graphed 
against the concentration at the center of the tissue, which was the region chosen because 
the drug uptake is fairly constant at this time, as well as the average concentration in all 
of the tissue.  Measurements were taken after 10 days because it is at this point that the 
drug concentration is well into steady state and should be fairly constant.  Figure 14 
below shows the results of this analysis.  
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Figure 14:  Mesh sensitivity analysis, number of elements versus concentration inside 
the tissue region. 
 
Figure 14 shows that the mesh converges around the original number of 1544 
elements. The change in computation time between 1544 elements and 2247 elements 
was negligible, so the original mesh with 1544 elements was used for the bulk of the 
analysis in this study.   
 
Next the variables used in our model were tested using the optimized mesh.  The 
variable that was the most difficult to find were the values for the diffusivity of the drug 
in the tissue region.   It was decided to use a diffusion constant of 1.5x10
-7 cm
2/s for 
Etonogestrel in the vaginal tissue and the mucus region.  This decision was based on the 
comparison of other studies where the same drug diffused in similar tissues.  To analyze 
the sensitivity of this constant on the model, different values for the diffusivity were used 
  - 13 - in the simulation.  Again tests were run over the 10 day period because it is safe to 
assume at the end of this time period that the drug concentration will be fairly constant. 
The diffusivity of Etonogestrel was varied greatly because it is important to see how it 
will affect the results of the model.  To compare how the diffusivity will affect the 
solution, the concentration of Etonogestrel was measured at Day 10, both at a single node 
in the center of the tissue region, and by computing the average concentration in the 
tissue.  The results of this are seen below in Figure 15. 
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Figure 15:  Diffusivity constant sensitivity analysis, diffusivity constant versus 
concentration in the tissue region. 
 
  From this analysis, it is very evident that the diffusivity greatly affects the output 
of this model.  A log scale was used for the x-axis because the values varied over a very 
large region with most of the change only occurring in a very small section of the graph.  
The greatest region of change in the results is when the tissue and mucosal diffusivity is 
between around 1 and 1000.  When the value for the diffusivity is below 1, Etonogestrel 
does not diffuse quickly enough in the tissue causing there to not be a high enough 
concentration in the tissue for the source removal term.  This causes FIDAP to output 
negative values for the concentration in the tissue, which is physically impossible.  For 
this reason, this region of the graph in inapplicable to the model 
 
  Similarly, when the value for the diffusivity is above 1000, Etonogestrel diffuses 
far too quickly in the tissue and mucus regions and stops affecting the solution to the 
model.  This is because at these high diffusivity values, Etonogestrel simple diffuses out 
  - 14 - of the system through the outer tissue boundary.  In the region between diffusivities of 1 
and 1000, the diffusivity value does not need to change much to drastically affect the 
solution.  The value found in the literature (97.403, non-dimensionalized) is within this 
region. 
 
  The source term used in the model is an approximation.  No published literature 
could be found on this because in reality, Etonogestrel is being carried away through the 
many capillaries present in the tissue.  For this reason the effect of the negative source 
term on the concentration in the tissue when the drug levels out to a solid rate was 
examined.  This can be seen below in Figure 16. 
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Figure 16:  Source term sensitivity analysis, source term versus concentration in the 
tissue region. 
 
  From this analysis it is clearly evident that the source term will directly influence 
the effective concentration that is found in the tissue throughout the simulation.  The 
connection between these two variables exhibits a positive relationship, in that when the 
source term is decreased the corresponding concentration in the vaginal tissue also 
decreases proportionally.  Therefore, depending on the size of the source term 
implemented in the problem definition, the concentration found in the tissue should 
respond accordingly.  This makes logical sense because the higher the rate that you are 
removing Etonogestrel from the tissue the region, then the lower the average 
concentration should be in the tissue itself.   
 
 
  - 15 - CONCLUSION 
 
  In modeling the contraceptive ring, the main objective was to test the claim that 
the ring releases a constant level of hormone to the blood. This was demonstrated through 
simulations of the 21-day period for which the ring is worn. Results showed that although 
the concentrations of the hormones Etonogestrel and Ethinyl Estradiol do decrease in the 
ring, the concentration in the tissue region around it stay constant. Investigations were 
also made as to whether the ring could be worn for an extra week, as the company claims 
it can. The NuvaRing was modeled for that extra 7-day period and it was shown that the 
drug release remains constant and that the ring is still effective.    
 
Economically speaking, the NuvaRing goes for about $75.00 for each ring. Other 
forms of birth control, such as the pill, all cost around the same. For example, a brand 
name birth control such as Ortho Tri-Cyclen can cost up to $85.00 for a month worth of 
pills (note – these values are not indicative of prices with insurance). The patch goes for 
about the same price as the pill, the Ortho Evra patch costing about $85.00 for three 
patches (a month’s worth). Although these prices vary with different distributors and 
insurance plans, they are not very different from each other.  
 
The contraceptive ring is considered to be much safer than other forms of birth 
control. It emphasizes its low dose of hormone, releasing only 11.1 mg/h/ml of estrogen 
into the body throughout a 21-day period compared to oral contraceptives which releases 
about 22.5 mg/h/ml and the patch, which releases 37.5 mg/h/ml. Because the ring only 
has to be inserted once, its release of hormones stays constant. It can be concluded that 
the NuvaRing is a safer and more effective form of birth control because of the overall 
lower dose of hormone that is constantly released, minimizing side effects such as 
nausea, mood swings, and possible blood clots 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  - 16 - APPENDIX A 
 
GOVERNING EQUATIONS: 
 
1) General species equation for the diffusion of Etonogestrel in the vaginal tissue  
 
a
a
a
a a r
x
c
D
x
c
u
t
c
+
∂
∂
=
∂
∂
+
∂
∂
2
2
  
 
2) Simplified species equation after the elimination of the convective terms 
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3) Non-dimensionalized species equation used for all simulations 
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note: concentration does not have to be non-dimensionalized 
 
BOUNDARY CONDITIONS & INITIAL CONDITIONS: 
 
Table A1: Summary of Boundary Conditions for Modeled System 
 
Boundary Region  Flux  
g/m
3s 
Conc. 
g/m
3
Outside Edge of Tissue  N/A  0 
Outside Edge of Mucus  0  N/A 
 
Table A2: Summary of Initial Conditions for Modeled System 
 
Region  Conc. 
g/m
3
Tissue 0 
Mucus 0 
Ring 9876.97 
  - 17 - INPUT PARAMETERS: 
 
Parameters (dimensional): 
Inner Radius of Ring    0.022225 m 
Cross Section Radius of Ring   0.0015875 m 
Thickness of Tissue    0.0032 m 
Thickness of Mucus    0.0005 m 
 
Time Step:    500 sec 
Ending Time    21 days = 1,814,400 sec 
 
Diffusivity: 
 -Ring   1.54  x  10
-13 m
2/s 
 -Tissue   1.50  x  10
-11 m
2/s 
 -Mucus   1.50  x  10
-11 m
2/s 
 
Etonogestrel concentration 
 -Ring   0  g/m
3
 -Tissue   0  g/m
3
 -Mucus   9876.97  g/m
3 
 
Source Term    -1.8332 x 10
-5 g/m
3s 
 
Parameters (non-dimensional): 
Note: used scaling factors of:   L = 0.0015875 mm and D = 1.54 x 10-
13m
2/s  
 
Inner Radius of Ring    14 
Cross Section Radius of Ring   1 
Thickness of Tissue    2.0157 
Thickness of Mucus    0.3149 
 
Time Step:    3.05344 x 10
-5
Ending Time    0.11087 
 
Diffusivity: 
 -Ring   1 
 -Tissue   97.403 
 -Mucus   97.403 
 
Etonogestrel concentration 
 -Ring   0  g/m
3
 -Tissue   0  g/m
3
 -Mucus   9876.97  g/m
3 
 
Source Term    -300 g/m
3
 
  - 18 - APPENDIX B 
 
PROBLEM STATEMENT: 
PROBLEM(axi-s, Isothermal, NoMomentum, Transient, LINEAR, FIXED, 
NEWTONIAN, INCOMPRESSIBLE, SPEC=1) 
 
Axi-Symmetric  The geometry is modeled as the cross section of the ring.  By 
rotating the circular geometry around the x-axis the ring is 
created. This creates a 2-D diffusion problem. 
Isothermal  The model is assumed to have a uniform temperature equal to 
37 degrees Celsius. 
No Momentum  There is no fluid flow or momentum in the vaginal cavity and 
therefore the Momentum Equation is not solved during 
simulation. 
Transient  The concentration throughout the tissue and ring changes over 
time. 
Linear  There is no convection or fluid flow present in the system and 
the convective term is eliminated in the governing equations. 
Fixed  The geometry does not deform. 
Newtonian  All materials are assumed to be incompressible. 
Incompressible  Newtonian  
Species 1  Etonogestrel is present in the system. 
 
SOLUTION STATEMENT 
 
SOLUTION (S.S.=50, VELCONV =0.001, RESCONV =0.01, SCHANGE =0, ACCF =0) 
 
TIME INTEGRATION STATEMENT 
 
TIMEINTEGRATION ( BACKWARD, Fixed, TSTART = 0, TEND = 0.11087, DT = 
3.05344e-005, NSTEPS = 3640 ) 
 
Backward  Using the implicit method 
Fixed  The time increment was constant for all steps 
note: there are no dimensions on the time  
Starting time  the starting time is at 0  
note: there are no dimensions on the time 
Ending time  Te ending time is set  to 0.11087  
note: there are no dimensions on the time 
Time increment  The time step is set to 3.05344 e -005  
note: there are no dimensions on the time 
Number of fixed 
steps 
There are  a maximum of 3640 time steps allowed  
 
  - 19 - ENTITY STATEMENT 
 
ENTITY( NAME = "TISSUE", SOLID, PROPERTY = "mat2" , SPEC=1, 
MDIFF="C1_TISSUE")  
 
ENTITY( NAME = "MUCUS", SOLID, PROPERTY = "mat2" , SPEC=1, 
MDIFF="C1_MUCUS") 
 
ENTITY( NAME = "RING", SOLID, PROPERTY = "mat1" , SPEC=1, 
MDIFF="C1_RING")  
 
ENTITY ( NAME = "TISSUE INTERFACE", PLOT ) 
 
ENTITY ( NAME = "TISSUE CAV TOP", PLOT ) 
 
ENTITY ( NAME = "TISSUE CAV BOT", PLOT ) 
 
DIFFUSIVITY STATEMENT 
  
DIFFUSIVITY ( SET = "C1_TISSUE", CONSTANT = 97.403 ) 
 
DIFFUSIVITY ( SET = "C1_MUCUS", CONSTANT = 97.403 ) 
 
DIFFUSIVITY ( SET = "C1_RING", CONSTANT = 1 ) 
 
BOUNDARY CONDITIONS STATEMENT 
  
ENTITY ( NAME = "TISSUE OUT", PLOT ) 
BCNODE ( SPEC=1, CONSTANT = 0, ENTITY = "TISSUE OUT" ) 
 
ENTITY ( NAME = "RING INTERFACE", PLOT ) 
 
ENTITY ( NAME = "MUCUS OUT", PLOT ) 
BCFLUX ( SPEC=1, CONSTANT = 0, ENTITY = "MUCUS OUT" ) 
  
INITIAL CONDITIONS STATEMENT 
  
ICNODE ( SPEC=1, CONSTANT = 0, ENTITY = "TISSUE" ) 
 
ICNODE ( SPEC=1, CONSTANT = 0, ENTITY = "MUCUS" ) 
 
ICNODE ( SPEC=1, CONSTANT = 9876.97, ENTITY = "RING" ) 
 
SOURCE TERM STATEMENT 
 
SOUR (SPEC = 1.0, CONS = -300.0, ENTI = "TISSUE") 
 
  - 20 - ELEMENT MESH 
 
Figure B1.  Sample meshes used to determine mesh convergence.  Please refer to Figure 
9 for convergence analysis graph. 
    
  (a)  582  Elements    (b)  1544  Elements 
 
Convergence Analysis: 
 
Table B1.  The number of nodes for each mesh that was produced. 
 
Mesh  Number of Elements 
1 331 
2 582 
3 909 
4 1544 
5 2247 
6 3616 
 
Note: Mesh #4 was used for all calculation steps and analysis. 
 
 
 
 
 
 
  - 21 - APPENDIX C 
Below are the 5 contour graphs seen in the results section with the colors inverted so that the 
concentration changes can be easily and thoroughly examined. 
 
 
 
Figure C1: Etonogestrel concentration variation at Day 1. 
 
 
 
Figure C2: Etonogestrel concentration variation at Day 3. 
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Figure C3: Etonogestrel concentration variation at Day 4. 
 
 
 
Figure C4: Etonogestrel concentration variation at Day 10. 
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Figure C5: Etonogestrel concentration variation at Day 21. 
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